When compared with the individuals in the healthy group, the expression of CXCR2, PTPRC, CCR2, MNDA, NCF2, S100A9, S100A8, and S100A12 was also upregulated in NAFLD patients. This evidence concerns the gene S100A9 and metabolic dysfunction-associated steatotic liver disease.